NCT07194382Phase 2Recruiting

AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF

Study sponsor: Avalyn Pharma Inc. · AVLN

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-12Estimated
Enrollment · participants160Estimated
Source updated2026-10-15Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source